Biocept, Inc.

Equities

BIOCQ

US09072V6002

Medical Equipment, Supplies & Distribution

Market Closed - OTC Markets Other stock markets 03:02:01 2024-04-23 pm EDT			5-day change	1st Jan Change
0.0001 ^USD	0.00%		0.00%	-99.76%

Apr. 02	Motion for Asset Sale Approved for Biocept, Inc.	CI
2023	Biocept, Inc.(OTCPK:BIOC.Q) dropped from NASDAQ Composite Index	CI

Biocept, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

August 14, 2023 at 04:05 pm EDT

Biocept, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 0.589 million compared to USD 5.82 million a year ago. Net loss was USD 3.63 million compared to USD 10.04 million a year ago. Basic loss per share from continuing operations was USD 3.5 compared to USD 17.82 a year ago. Diluted loss per share from continuing operations was USD 3.5 compared to USD 17.82 a year ago.
For the six months, sales was USD 1.26 million compared to USD 25.76 million a year ago. Net loss was USD 10.78 million compared to USD 12.26 million a year ago. Basic loss per share from continuing operations was USD 13.25 compared to USD 21.78 a year ago. Diluted loss per share from continuing operations was USD 13.25 compared to USD 21.78 a year ago.

Latest news about Biocept, Inc.

Motion for Asset Sale Approved for Biocept, Inc.	Apr. 02	CI
Biocept, Inc.(OTCPK:BIOC.Q) dropped from NASDAQ Composite Index	23-10-24	CI
Biocept, Inc.(NasdaqCM:BIOC) dropped from S&P TMI Index	23-10-19	CI
Biocept, Inc. Filed for Bankruptcy	23-10-13	CI
Biocept, Inc. Announces the Full Enrollment of 40 Subjects with Breast or Non-Small Cell Lung Cancer	23-09-21	CI
Sector Update: Health Care Stocks Slipping Late Friday8 Afternoon	23-09-08	MT
Sector Update: Health Care Stocks Slipping Friday Afternoon	23-09-08	MT
Sector Update: Health Care	23-09-08	MT
Biocept Signs Non-Exclusive Licensing Agreement With Plus Therapeutics on CNSide Tumor Cell Platform	23-09-08	MT
Wall Street Set to Open Flat Friday as Investors Remain Wary of Potential Interest Rate Hike	23-09-08	MT
Top Premarket Gainers	23-09-08	MT
Plus Therapeutics, Inc. Enters into License Agreement with Biocept for Cerebrospinal Fluid Tumor Cell Enumeration Assay	23-09-08	CI
Transcript : Biocept, Inc. - Special Call	23-08-30
Certain Warrants of Biocept, Inc. are subject to a Lock-Up Agreement Ending on 24-AUG-2023.	23-08-23	CI
Certain Stock Options of Biocept, Inc. are subject to a Lock-Up Agreement Ending on 24-AUG-2023.	23-08-23	CI
Certain Series A Convertible Preferred Stock of Biocept, Inc. are subject to a Lock-Up Agreement Ending on 24-AUG-2023.	23-08-23	CI
Certain Common Stock of Biocept, Inc. are subject to a Lock-Up Agreement Ending on 24-AUG-2023.	23-08-23	CI
Earnings Flash (BIOC) BIOCEPT Reports Q2 Revenue $589,000	23-08-14	MT
Biocept, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Biocept Says Board Chair Faye Wilson Died	23-07-14	MT
Biocept Names Antonino Morales as President, CEO	23-06-20	MT
Biocept, Inc. Appoints Antonino Morales as Chief Executive Officer	23-06-20	CI
Biocept, Inc. Announces Executive Changes	23-06-20	CI
Top Midday Decliners	23-05-25	MT
Biocept Prices $5 Million Offering of Common Stock, Warrants	23-05-25	MT

Chart Biocept, Inc.

Duration

Period

More charts

Company Profile

Biocept, Inc. is a molecular oncology diagnostics company. The Company focuses on developing and commercializing clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor deoxyribonucleic acid (DNA) from blood and cerebrospinal fluid (CSF). Its product is branded and trademarked under the name CNSide. CNSide encompasses a suite of cellular and molecular technologies intended to aid medical professionals in CSF analysis and central nervous system (CNS) disease management in patients with solid tumors. It offers and conducts its commercialized diagnostic assays, which include cell capture and enumeration, immunocytochemistry, fluorescent in situ hybridization (FISH), and next generation sequencing (NGS). It has commercialized its CNSide assays for detecting and characterizing many different carcinomas and melanoma. These assays utilize its dual cellular and ctDNA technology platforms and provide biomarker analysis from a patientâs CSF sample.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-14 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.0001

Average target price

Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
BIOCEPT, INC.	-99.76%	262
BIOMÉRIEUX	+0.89%	12.8B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-10.29%	7.61B
DIASORIN S.P.A.	+1.78%	5.41B
AUTOBIO DIAGNOSTICS CO., LTD.	-1.16%	4.51B
LANTHEUS HOLDINGS, INC.	+5.74%	4.49B
10X GENOMICS, INC.	-50.70%	3.29B
ANDON HEALTH CO., LTD.	+12.21%	2.73B
VITROLIFE AB	-16.13%	2.02B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-11.50%	1.73B

Diagnostic & Testing Substances